Erlotinib Effective and With Fewer Side-Effects after First-Line Treatment, Institute of Oncology Ion Chiricuta Study
Physorg.com -- The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.